Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Group Testing Performance Evaluation for SARS-COV-2 Massive Scale Screening and Testing

View ORCID ProfileOzkan Ufuk Nalbantoglu
doi: https://doi.org/10.1101/2020.05.02.20080390
Ozkan Ufuk Nalbantoglu
Department of Computer Engineering and Genome and Stem Cell Center, Erciyes University, Kayseri, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ozkan Ufuk Nalbantoglu
  • For correspondence: nalbantoglu@erciyes.edu.tr
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

The capacity of current molecular testing convention does not allow high-throughput and community level scans of COVID-19 infections. The diameter in current paradigm of shallow tracing is unlikely to reach the silent clusters that might be as important as the symptomatic cases in the spread of the disease. Group testing is a feasible and promising approach when the resources are scarce and when a relatively low prevalence regime is observed on the population. We employed group testing with a sparse random pooling scheme and conventional group test decoding algorithms both for exact and inexact recovery. Our simulations showed that significant reduction in per case test numbers (or expansion in total test numbers preserving the number of actual tests conducted) for very sparse prevalence regimes is available. Currently proposed COVID-19 group testing schemes offer a gain up to 10X scale-up. There is a good probability that the required scale up to achieve massive scale testing might be greater in certain scenarios. We investigated if further improvement is available, especially in sparse prevalence occurrence where outbreaks are needed to be avoided by population scans. Our simulations show that sparse random pooling can provide improved efficiency gains compared to row-column group testing or Reed-Solomon error correcting codes. Therefore, we propose that special designs for different scenarios could be available and it is possible to scale up testing capabilities significantly.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No related funding was received for the study

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All code is available, please contract the author at ufuknalbantoglu{at}yahoo.com

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted May 05, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Group Testing Performance Evaluation for SARS-COV-2 Massive Scale Screening and Testing
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Group Testing Performance Evaluation for SARS-COV-2 Massive Scale Screening and Testing
Ozkan Ufuk Nalbantoglu
medRxiv 2020.05.02.20080390; doi: https://doi.org/10.1101/2020.05.02.20080390
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Group Testing Performance Evaluation for SARS-COV-2 Massive Scale Screening and Testing
Ozkan Ufuk Nalbantoglu
medRxiv 2020.05.02.20080390; doi: https://doi.org/10.1101/2020.05.02.20080390

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (239)
  • Allergy and Immunology (521)
  • Anesthesia (124)
  • Cardiovascular Medicine (1418)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (582)
  • Epidemiology (10288)
  • Forensic Medicine (6)
  • Gastroenterology (527)
  • Genetic and Genomic Medicine (2625)
  • Geriatric Medicine (254)
  • Health Economics (496)
  • Health Informatics (1729)
  • Health Policy (789)
  • Health Systems and Quality Improvement (671)
  • Hematology (266)
  • HIV/AIDS (564)
  • Infectious Diseases (except HIV/AIDS) (12083)
  • Intensive Care and Critical Care Medicine (648)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (288)
  • Neurology (2456)
  • Nursing (144)
  • Nutrition (377)
  • Obstetrics and Gynecology (491)
  • Occupational and Environmental Health (566)
  • Oncology (1320)
  • Ophthalmology (400)
  • Orthopedics (146)
  • Otolaryngology (235)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (342)
  • Pediatrics (778)
  • Pharmacology and Therapeutics (329)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2395)
  • Public and Global Health (4999)
  • Radiology and Imaging (893)
  • Rehabilitation Medicine and Physical Therapy (525)
  • Respiratory Medicine (681)
  • Rheumatology (309)
  • Sexual and Reproductive Health (255)
  • Sports Medicine (244)
  • Surgery (297)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)